Our findings are the first to demonstrate that GCLC desuccinylation mediated by SIRT2 directly regulates the rapid activation of GCLC upon oxidative stress, which provides a promising adjunct therapeutic target for cancer treatment. The gene discussed is SIRT2; the disease is cancer.